Heart risk study for people with stage 4 kidney disease
Part of Heart & circulation clinical trials.
This study looks at a protein called lipoprotein(a) in the blood to see if it predicts heart problems in people with stage 4 chronic kidney disease who are not on dialysis or transplant. Following participants for 18 months, it aims to find ways to better manage heart risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 4 chronic kidney disease and are not on dialysis or had a kidney transplant
- You can be followed for 18 months
- You are covered by French health insurance
- You are not currently in another study or in a waiting period from one
- You do not have familial high cholesterol or severe obesity (BMI over 40)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at the link between kidney disease and heart disease. It aims to understand how heart problems affect people with chronic kidney disease. The trial does not test a new drug, but rather follows patients to learn more about their health.
This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.
This study looks at heart imaging scans in people with kidney disease to find early signs of heart problems. Researchers will use special imaging already planned as part of your normal care to see if it can help identify who needs heart treatment.
This study looks for new markers in blood or urine that may help explain heart (cardiovascular) risk in people with chronic kidney disease. It may help doctors better predict risk, especially in those not yet on dialysis.
This study looks at how heart and kidney problems affect people with advanced heart failure. It aims to understand how these conditions together impact your health and outcomes.
This study looks at how a body receptor (called the A2A receptor) works in people with high “bad” cholesterol (LDL). It compares people with high LDL to people with normal LDL to better understand cholesterol-related biology.
Hear when a new CKD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.